Gut Microbiota and Metabolic Syndrome
Metabolic syndrome (MetS) represents a cluster of interrelated risk factors—including obesity, hyperglycemia, dyslipidemia, hypertension, hyperuricemia, and non-alcoholic fatty liver disease (NAFLD)—that collectively elevate the risk of cardiovascular and cerebrovascular diseases. The pathogenesis of MetS involves insulin resistance, chronic inflammation, autonomic dysfunction, and oxidative stress. Emerging research highlights the gut microbiota as a critical environmental factor influencing host metabolism and the development of MetS. This article synthesizes current evidence on the role of gut microbiota dysbiosis in MetS, its mechanisms of action, and potential therapeutic interventions targeting the gut microbiome.
Gut Microbiota Composition in Metabolic Syndrome
The human gut harbors over 1,000 bacterial species, encoding approximately 3 million genes. These microbes produce metabolites with both beneficial and harmful effects on host physiology. Dysbiosis—characterized by an imbalance between beneficial and pathogenic bacteria—is consistently observed in individuals with MetS.
Obesity
Obesity, a central component of MetS, is strongly linked to gut microbiota alterations. High-fat diets in mice increase the abundance of Firmicutes and Proteobacteria while reducing Bacteroidetes and Verrucomicrobia. In humans, obesity correlates with reduced microbial diversity and shifts in specific taxa. For instance, Akkermansia muciniphila, a mucin-degrading bacterium associated with metabolic health, is often depleted in obese individuals. Fei et al. demonstrated that transplanting Enterobacter cloacae B29—isolated from an obese human—into germ-free mice induced obesity and insulin resistance under high-fat diets, underscoring the microbiota’s causal role in metabolic dysfunction.
Hyperglycemia and Type 2 Diabetes
Gut microbiota dysbiosis in type 2 diabetes mellitus (T2DM) is marked by reduced butyrate-producing bacteria (e.g., Roseburia, Faecalibacterium) and increased pathogens. Butyrate, a short-chain fatty acid (SCFA), enhances gut barrier integrity, reduces inflammation, and improves insulin sensitivity. Zhou et al. found that Zucker diabetic fatty rats exhibited age-dependent shifts in fecal microbiota, with Lactobacillus dominating early stages and Bifidobacterium emerging later, suggesting dynamic microbial contributions to disease progression.
Dyslipidemia
Abnormal lipid profiles in MetS correlate with gut microbiota changes. High-glucose or high-fructose diets in mice reduce Bacteroidetes and increase Proteobacteria, exacerbating hepatic lipid accumulation. Human studies reveal that unfavorable lipid profiles (elevated triglycerides, low HDL) associate with low microbial diversity and altered abundances of Actinobacteria, Proteobacteria, and Bacteroidetes. Wang et al. estimated that 4.5% of BMI variation and 6% of triglyceride levels are attributable to gut microbiota composition.
Hypertension
Hypertensive individuals exhibit reduced microbial diversity, increased Firmicutes/Bacteroidetes ratios, and decreased SCFA-producing bacteria. Li et al. identified Prevotella and Klebsiella overgrowth in pre-hypertensive and hypertensive patients, linking these taxa to inflammation and endothelial dysfunction. Fecal microbiota transplantation (FMT) from hypertensive humans to germ-free mice elevated blood pressure, confirming microbiota’s direct role in hypertension.
Hyperuricemia and Gout
Gut microbiota dysbiosis in hyperuricemia involves reduced Firmicutes and increased Bacteroidetes. Guo et al. observed elevated Bacteroides caccae and diminished Fecalibacterium prausnitzii in gout patients, suggesting microbial modulation of purine metabolism and uric acid excretion.
NAFLD and OSAHS
NAFLD, a hepatic manifestation of MetS, is driven by gut-derived endotoxins and bacterial metabolites. Yuan et al. identified Klebsiella pneumoniae strains in NAFLD patients that produce ethanol, mimicking alcohol-induced liver damage. Obstructive sleep apnea hypopnea syndrome (OSAHS) associates with reduced SCFA-producing bacteria and elevated pro-inflammatory cytokines like IL-6, highlighting microbiota’s role in metabolic comorbidities.
Mechanisms Linking Gut Microbiota to Metabolic Syndrome
Gut Barrier Dysfunction and Inflammation
A compromised intestinal barrier permits bacterial translocation, triggering systemic inflammation. Dysbiosis reduces mucus-producing goblet cells and antimicrobial peptides, allowing lipopolysaccharides (LPS) from Gram-negative bacteria to enter circulation. LPS activates Toll-like receptor 4 (TLR4), inducing pro-inflammatory cytokines (e.g., TNF-α, IL-6) that promote insulin resistance and endothelial dysfunction. Chronic low-grade inflammation perpetuates metabolic disorders, creating a vicious cycle.
Short-Chain Fatty Acids (SCFAs)
SCFAs—acetate, propionate, and butyrate—are fermentation products of dietary fiber. Butyrate enhances gut barrier function by upregulating tight junction proteins (e.g., occludin, claudin-1) and stimulating mucin production. Propionate and acetate modulate appetite via GLP-1 and PYY secretion, reducing food intake. SCFAs also activate AMP-activated protein kinase (AMPK) in skeletal muscle, enhancing fatty acid oxidation and glucose uptake. Depletion of SCFA-producing bacteria in MetS disrupts these regulatory mechanisms, contributing to obesity and insulin resistance.
Bile Acid Metabolism
Bile acids, synthesized from cholesterol in the liver, regulate lipid digestion and glucose homeostasis. Gut microbiota metabolize primary bile acids into secondary bile acids via bile salt hydrolase (BSH) activity. These metabolites activate farnesoid X receptor (FXR) and G protein-coupled bile acid receptor 1 (TGR5), modulating lipid metabolism and GLP-1 secretion. Dysbiosis alters bile acid pools, impairing FXR/TGR5 signaling and exacerbating metabolic dysfunction. For example, Bacteroides species deconjugate bile acids, reducing their reabsorption and increasing fecal excretion.
Therapeutic Strategies Targeting Gut Microbiota
Probiotics and Prebiotics
Probiotics (e.g., Lactobacillus, Bifidobacterium) and prebiotics (e.g., inulin, resistant starch) restore microbial balance. In a randomized trial, Lactobacillus reuteri V3401 reduced IL-6 and vascular adhesion molecules in MetS patients. High-fiber diets enriched SCFA-producing bacteria (Prevotella, Bifidobacterium) in T2DM patients, improving glycemic control through GLP-1 upregulation.
Fecal Microbiota Transplantation (FMT)
FMT from lean donors to MetS patients enhanced insulin sensitivity and microbial diversity. Vrieze et al. reported a 2.5-fold increase in butyrate-producing Roseburia post-FMT, correlating with metabolic improvements.
Metabolic Surgery
Bariatric procedures (e.g., Roux-en-Y gastric bypass) alter gut anatomy, reducing Firmicutes and increasing Proteobacteria. These shifts correlate with weight loss, improved lipid profiles, and remission of T2DM, partly mediated by microbiota-derived metabolites.
Pharmacological Interventions
Metformin, a first-line T2DM drug, enriches Akkermansia and inhibits Bacteroides fragilis, increasing bile acids (e.g., glycoursodeoxycholic acid) that antagonize FXR and improve glucose homeostasis. Liraglutide, a GLP-1 agonist, reduces obesity-associated bacteria (Lactobacillus, Clostridium) and enhances lean microbiota phenotypes.
Conclusion
The gut microbiota is a pivotal regulator of metabolic health, influencing inflammation, energy harvest, and hormone signaling. Dysbiosis in MetS manifests as reduced microbial diversity, pathogenic overgrowth, and diminished beneficial taxa. Mechanistically, gut barrier defects, SCFA depletion, and bile acid dysmetabolism drive insulin resistance and systemic inflammation. Therapeutic strategies—probiotics, FMT, and microbiota-modulating drugs—hold promise for MetS management. However, human studies remain inconclusive, necessitating larger trials to validate causality and optimize interventions. Harnessing the gut microbiota’s potential could revolutionize the prevention and treatment of metabolic disorders.
doi: 10.1097/CM9.0000000000000696
Was this helpful?
0 / 0